BR112013002211A2 - 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-met - Google Patents
6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-metInfo
- Publication number
- BR112013002211A2 BR112013002211A2 BR112013002211A BR112013002211A BR112013002211A2 BR 112013002211 A2 BR112013002211 A2 BR 112013002211A2 BR 112013002211 A BR112013002211 A BR 112013002211A BR 112013002211 A BR112013002211 A BR 112013002211A BR 112013002211 A2 BR112013002211 A2 BR 112013002211A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- met
- inhibitor
- ylthio
- indazol
- Prior art date
Links
- -1 1-methyl-1h-pyrazol-4-yl Chemical group 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36933510P | 2010-07-30 | 2010-07-30 | |
| PCT/US2011/044926 WO2012015677A1 (en) | 2010-07-30 | 2011-07-22 | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013002211A2 true BR112013002211A2 (pt) | 2016-05-24 |
Family
ID=44513148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013002211A BR112013002211A2 (pt) | 2010-07-30 | 2011-07-22 | 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-met |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8268836B2 (https=) |
| EP (1) | EP2598144B1 (https=) |
| JP (1) | JP5738412B2 (https=) |
| KR (1) | KR20130052740A (https=) |
| CN (1) | CN103002898A (https=) |
| AR (1) | AR085183A1 (https=) |
| AU (1) | AU2011282973B2 (https=) |
| BR (1) | BR112013002211A2 (https=) |
| CA (1) | CA2805494A1 (https=) |
| EA (1) | EA201270818A1 (https=) |
| ES (1) | ES2516940T3 (https=) |
| IN (1) | IN2012MN02924A (https=) |
| MX (1) | MX2013001247A (https=) |
| TW (1) | TWI431008B (https=) |
| WO (1) | WO2012015677A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169532A1 (en) * | 2012-05-09 | 2013-11-14 | Eli Lilly And Company | Anti-c-met antibodies |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US10386376B2 (en) | 2015-11-09 | 2019-08-20 | Jeimei, Llc | Sample container with integrated test strip |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080584A (ko) * | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| CN101558070A (zh) * | 2006-10-23 | 2009-10-14 | Sgx药品公司 | 三唑并哒嗪蛋白激酶调节剂 |
| KR101083177B1 (ko) | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| UY31676A1 (es) | 2008-02-28 | 2009-09-30 | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" |
-
2011
- 2011-07-20 AR ARP110102632A patent/AR085183A1/es unknown
- 2011-07-22 AU AU2011282973A patent/AU2011282973B2/en not_active Expired - Fee Related
- 2011-07-22 JP JP2013521838A patent/JP5738412B2/ja not_active Expired - Fee Related
- 2011-07-22 MX MX2013001247A patent/MX2013001247A/es not_active Application Discontinuation
- 2011-07-22 WO PCT/US2011/044926 patent/WO2012015677A1/en not_active Ceased
- 2011-07-22 EA EA201270818A patent/EA201270818A1/ru unknown
- 2011-07-22 CA CA2805494A patent/CA2805494A1/en not_active Abandoned
- 2011-07-22 CN CN2011800371928A patent/CN103002898A/zh active Pending
- 2011-07-22 TW TW100126076A patent/TWI431008B/zh not_active IP Right Cessation
- 2011-07-22 EP EP11741372.4A patent/EP2598144B1/en not_active Not-in-force
- 2011-07-22 ES ES11741372.4T patent/ES2516940T3/es active Active
- 2011-07-22 US US13/188,496 patent/US8268836B2/en not_active Expired - Fee Related
- 2011-07-22 KR KR1020137002382A patent/KR20130052740A/ko not_active Ceased
- 2011-07-22 BR BR112013002211A patent/BR112013002211A2/pt not_active IP Right Cessation
-
2012
- 2012-12-31 IN IN2924MUN2012 patent/IN2012MN02924A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI431008B (zh) | 2014-03-21 |
| KR20130052740A (ko) | 2013-05-23 |
| JP5738412B2 (ja) | 2015-06-24 |
| EA201270818A1 (ru) | 2013-05-30 |
| US20120028984A1 (en) | 2012-02-02 |
| AU2011282973B2 (en) | 2014-03-20 |
| WO2012015677A9 (en) | 2012-12-13 |
| EP2598144B1 (en) | 2014-08-13 |
| AR085183A1 (es) | 2013-09-18 |
| JP2013532687A (ja) | 2013-08-19 |
| US8268836B2 (en) | 2012-09-18 |
| ES2516940T3 (es) | 2014-10-31 |
| CN103002898A (zh) | 2013-03-27 |
| MX2013001247A (es) | 2013-03-18 |
| IN2012MN02924A (https=) | 2015-06-12 |
| CA2805494A1 (en) | 2012-02-02 |
| WO2012015677A1 (en) | 2012-02-02 |
| AU2011282973A1 (en) | 2013-01-10 |
| TW201219393A (en) | 2012-05-16 |
| EP2598144A1 (en) | 2013-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013002211A2 (pt) | 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-il tio)-[1,2,4]triazolo[43-b] piridazina como um inibidor de c-met | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| CU24097B1 (es) | Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas | |
| BR112012019302A2 (pt) | imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met | |
| CL2013002688A1 (es) | Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer. | |
| MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
| MX2009004060A (es) | Moduladores de proteina cinasa de triazolpiridazina. | |
| NZ626937A (en) | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors | |
| IN2014MN02497A (https=) | ||
| IN2014DN07384A (https=) | ||
| ZA201306348B (en) | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | |
| BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
| JOP20130313B1 (ar) | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه | |
| WO2014018881A8 (en) | Atx modulating agents | |
| MX2014015346A (es) | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. | |
| MY162950A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| PH12013501758A1 (en) | Pyrazolo [1,5-a] pyridines as trk inhibitors | |
| WO2012135675A3 (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
| IL235659A0 (en) | History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| BR112016029825A2 (pt) | composto | |
| MX340574B (es) | Imidazo pirazinas. | |
| CL2011001947A1 (es) | Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular. | |
| PH12013500293A1 (en) | Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |